An Open Label Extension Study of the Efficacy of MORAb-003

Stopped early · Phase 2

Conditions studied: Epithelial Ovarian Cancer

In brief

An open label extension of the MORAb-003-002 study in order to continue the active patients in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is closed.

Key facts

Study ID

NCT01018563

Run by

Morphotek

People needed

3

Starts

2010-01-13

Expected to finish

2013-03-05

Last updated by the study team

2021-12-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Provision of Informed consent.
• Subjects must have been enrolled in and have met the inclusion/exclusion criteria of the MORAb-003-002 study.
• Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or stable disease and an investigator's assessment of a clinical benefit) after MORAb-003 in combination with standard chemotherapy and have not yet met the criteria for disease progression during participation in the MORAb-003-002 study.
• Subjects must be currently receiving single-agent MORAb-003 maintenance therapy.

You may not qualify if…

• Subjects that discontinued the MORAb-003-002 study for any reason.

Where it is running

• Sharp Memorial Hospital — Chula Vista, California, United States
• South Texas Oncology & Hematology — San Antonio, Texas, United States
• Nationales Centrum fur Tumorerkrandungen — Heidelberg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.